We can’t show the full text here under this license. Use the link below to read it at the source.
Glucagon-Like Peptide-1 Receptor Agonist-Experienced Adults with Type 2 Diabetes Switching to Once-Weekly Semaglutide in a Real-World Setting: SURE Program Post Hoc Analysis
Adults with Type 2 Diabetes Already Using Similar Medicines Switching to Once-Weekly Semaglutide in Everyday Care
AI simplified
Abstract
Of the 3,505 patients analyzed, 651 switched to once-weekly semaglutide, resulting in a 0.67%-point reduction in glycosylated hemoglobin (HbA).
- Patients who switched to once-weekly semaglutide experienced a 3.69-kg reduction in body weight over 30 weeks.
- 27.6% of patients achieved a body weight reduction of ≥ 5%.
- 33.3% of patients with baseline HbA ≥ 7% achieved HbA < 7% by the end of the study.
- No new safety concerns were identified during the analysis.
AI simplified
Key numbers
0.67%
Reduction in HbA
Change in HbA after switching to OW semaglutide over 30 weeks.
3.69 kg
Weight Loss
Average body weight reduction after 30 weeks of treatment.
163 of 591
Achieved Weight Reduction
Patients achieving a body weight reduction of ≥ 5%.